GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Earnings per Share (Diluted)

Alliance Pharma (LSE:APH) Earnings per Share (Diluted) : £-0.01 (TTM As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Earnings per Share (Diluted)?

Alliance Pharma's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01.

Alliance Pharma's EPS (Basic) for the six months ended in Jun. 2023 was £0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01.

Alliance Pharma's EPS without NRI for the six months ended in Jun. 2023 was £0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was £0.03.

During the past 12 months, Alliance Pharma's average EPS without NRIGrowth Rate was -52.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -5.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.00% per year.

During the past 13 years, Alliance Pharma's highest 3-Year average EPS without NRI Growth Rate was 184.40% per year. The lowest was -75.00% per year. And the median was 4.70% per year.


Alliance Pharma Earnings per Share (Diluted) Historical Data

The historical data trend for Alliance Pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Earnings per Share (Diluted) Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.05 0.02 0.01 -

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - 0.02 -0.02 0.01

Competitive Comparison of Alliance Pharma's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's PE Ratio falls into.



Alliance Pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Alliance Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.936-0)/545.281
=0.00

Alliance Pharma's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(5.109-0)/541.576
=0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Alliance Pharma  (LSE:APH) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alliance Pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q1 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amphenol Announces Third Quarter 2023 Dividend

By Business Wire 08-04-2023

Q4 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024